ID

13630

Descripción

Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors https://de.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors http://www.ncbi.nlm.nih.gov/pubmed/19097774

Link

https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors

Palabras clave

Versiones (1)
  1. 22/2/16 22/2/16 - Martin Dugas
Titular de derechos de autor

Eisenhauer EA

Subido en

22 de febrero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

RECIST

Alemán Inglés

Response Evaluation Criteria in Solid Tumors

1 formularios  
Response Evaluation Criteria in Solid Tumors
Descripción

Response Evaluation Criteria in Solid Tumors

Alias
UMLS CUI-1
C1709926
Evaluation of target lesions
Descripción

Evaluation of target lesions

Tipo de datos

text

Alias
UMLS CUI [1]
C2986558
Evaluation of non-target lesions
Descripción

Evaluation of non-target lesions

Tipo de datos

text

Alias
UMLS CUI [1]
C2986559
Best overall response
Descripción

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria - Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be classified as having “symptomatic deterioration”. Every effort should be made to document the objective progression even after discontinuation of treatment. - In some circumstances it may be difficult to distinguish residual disease from normal tissue. When the evaluation of complete response depends on this determination, it is recommended that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the complete response status.

Tipo de datos

text

Alias
UMLS CUI [1]
C2986560
Duration of stable disease
Descripción

SD is measured from the start of the treatment until the criteria for disease progression are met, taking as reference the smallest measurements recorded since the treatment started. The clinical relevance of the duration of SD varies for different tumor types and grades. Therefore, it is highly recommended that the protocol specify the minimal time interval required between two measurements for determination of SD. This time interval should take into account the expected clinical benefit that such a status may bring to the population under study.

Tipo de datos

durationDatetime

Alias
UMLS CUI [1,1]
C0677946
UMLS CUI [1,2]
C0449238
Volver a la parte superior de la página

Similar models

Response Evaluation Criteria in Solid Tumors

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Response Evaluation Criteria in Solid Tumors
C1709926 (UMLS CUI-1)
Item
Evaluation of target lesions
text
C2986558 (UMLS CUI [1])
Evaluation of target lesions
Code List
Evaluation of target lesions
CL Item
Complete Response: Disappearance of all target lesions (CR)
C1275810 (UMLS CUI-1)
CL Item
Partial Response: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD (PR)
C1275833 (UMLS CUI-1)
CL Item
Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started (SD)
C0677946 (UMLS CUI-1)
CL Item
Progressive Disease: At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (PD)
C1335499 (UMLS CUI-1)
Item
Evaluation of non-target lesions
text
C2986559 (UMLS CUI [1])
Evaluation of non-target lesions
Code List
Evaluation of non-target lesions
CL Item
Complete Response: Disappearance of all non-target lesions and normalization of tumor marker level (CR)
C1275810 (UMLS CUI-1)
CL Item
Incomplete Response/ Stable Disease: Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits (SD)
C0677946 (UMLS CUI-1)
CL Item
Progressive Disease: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions (PD)
C1335499 (UMLS CUI-1)
Item
Best overall response
text
C2986560 (UMLS CUI [1])
Best overall response
Code List
Best overall response
CL Item
Complete Response (CR)
C1275810 (UMLS CUI-1)
CL Item
Partial Response (PR)
C1275833 (UMLS CUI-1)
CL Item
Stable Disease (SD)
C0677946 (UMLS CUI-1)
CL Item
Progressive Disease (PD)
C1335499 (UMLS CUI-1)
Duration of stable disease
Item
Duration of stable disease
durationDatetime
C0677946 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial